SCHEMBL414474

SCHEMBL414474

CNCc1cccc(C)c1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 3/20 0.44
KDM4E B2RXH2 3/20 0.43
POLB P06746 2/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
CRHBP P24387 1/20 0.43
MAPK1 P28482 1/20 0.43
CRHR2 Q13324 1/20 0.43
SLC6A4 P31645 8/20 0.41
HTR2A P28223 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SLC6A2 P23975 7/20 0.40
SLC6A3 Q01959 7/20 0.40
KCNH2 Q12809 1/20 0.39
GPR84 Q9NQS5 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1251940 0.81 SLC6A4 (0.41) SCN8ATSHRSLC6A4HTR2AKMT2A
SCHEMBL29875218 0.81 ALDH1A1 (0.58) KDM4EPOLBGAAALDH1A1TSHR
SCHEMBL680393 0.81 ALDH1A1 (0.58) KDM4EPOLBGAAALDH1A1TSHR
SCHEMBL1254150 0.79 SLC6A4 (0.47) POLBSLC6A4HTR2AMEN1KMT2A
SCHEMBL414666 0.79 MCL1 (0.49) SCN8AKDM4EPOLBGAAALDH1A1
SCHEMBL16473764 0.79 SCN8A (0.44) SCN8AKDM4EALDH1A1SLC6A4HTR2A
Hydrochloric Acid SCHEMBL7563580 0.78 KMT2A (0.42) KDM4EPOLBGAAALDH1A1TSHR
SCHEMBL13344106 0.78 GABRA1 (0.43) SCN8AKDM4EALDH1A1TSHRMAPK1
SCHEMBL16473772 0.78 SCN4A (0.49) SCN8ATSHRSLC6A4HTR2ASLC6A2
SCHEMBL8567856 0.78 KMT2A (0.43) SCN8APOLBALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed
EP-2376431-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2011-10-19 EP disclosed
WO-2010066847-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS CELLVIR (FR) 2010-06-17 WO disclosed
EP-2196453-A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents Cellvir (FR) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 SCN8A 4414/4885KDM4E 674/4885POLB 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.